by H.S. Ayoub
BioHealth Investor.com
Biotechnology
IDM PHARMA INC [IDMI] +38.16%
CELL GENESYS INC [CEGE] +32.25%
OPEXA THERAPEUTICS [OPXA] +27.95%
BIOMIRA INC [BIOM] +16.24%
ACADIA PHARMACEUTICA [ACAD] +12.09%
Diagnostic Substances
REMOTEMDX INC [RMDX.OB] +5.52%
ROSETTA GENOMICS LTD [ROSG] +5.10%
ISTA PHARMACTLS [ISTA] +4.77%
GENE LOGIC INC [GLGC] +4.69%
NEOGEN CP [NEOG] +3.48%
Drug Delivery
BIOVAIL CORP [BVF] +5.80%
BENTLEY PHARMACEUTIC [BNT] +2.75%
NEKTAR THERAPEUTIC [NKTR] +2.46%
ELAN CP PLC ADR [ELN] +2.32%
COLUMBIA LABS INC [CBRX] +2.26%
Drug Manufacturers
AVANIR PHARMACEUTICL [AVNR] +8.40%
OSCIENT PHARMACEUT [OSCI] +6.97%
NITROMED, INC. [NTMD] +5.41%
DR. REDDY’S LAB LTD [RDY] +5.12%
ADVANCIS PHARMA CP [AVNC] +4.98%
Drug Related Products
XELR8 HOLDINGS, INC [BZI] +5.76%
PRESTIGE BRAND HLGS [PBH] +2.68%
MEDICAL NUTRITN USA [MDNU.OB] +2.33%
PERRIGO COMPANY [PRGO] +2.02%
TIENS BIOTECH GR USA [TBV] +1.70%
Generic Drugs
PHARMACUTICAL CO [PRX] +3.20%
HI-TECH PHARMACAL [HITK] +1.64%
CATALYST PHARMACEUTI [CPRX] +1.38%
CARACO PHARMA LABS [CPD] +0.81%
MYLAN LABS INC [MYL] +0.48%
Medical Appliances & Equipment
MEDIS TECH LTD [MDTL] +8.37%
NXSTAGE MEDICAL, INC [NXTM] +6.45%
SYNERGETICS USA INC [SURG] +5.52%
ALIGN TECHNOLOGY I [ALGN] +5.27%
CYNOSURE, INC. [CYNO] +5.27%
Medical Instruments & Supplies
BIOFORCE NANOSCIENCE [BFNH.OB] +30.77%
CANTEL MEDICAL CORP [CMN] +5.91%
TUTOGEN MEDICAL INC [TTG] +5.90%
VITAL SIGNS INC [VITL] +5.83%
CRYOCOR, INC. [CRYO] +5.22%
Medical Laboratories & Research
AETERNA ZENTARIS [AEZS] +2.53%
BIO-REFERENCE LAB [BRLI] +2.29%
RADNET INC [RDNT] +2.26%
ENZO BIOCHEM INC [ENZ] +2.25%
QUEST DIAGNOSTC [DGX] +1.98%
http://www.biohealthinvestor.com/
Buffett Missed These Two…
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.